China Biologic Products 10-Q 4 Aug 16 2016 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2016	Aug. 04, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q2
Entity Registrant Name	China Biologic Products, Inc.
Entity Central Index Key	1,369,868
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Trading Symbol	CBPO
Entity Common Stock, Shares Outstanding		26,892,701

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Current Assets
Cash and cash equivalents	$ 204,033,989	$ 144,937,893
Time deposits	0	38,032,593
Accounts receivable, net of allowance for doubtful accounts	38,258,676	25,144,969
Inventories	136,038,217	126,395,312
Prepayments and other current assets, net of allowance for doubtful accounts	21,587,018	24,545,597
Deposits related to land use rights, current portion	4,901,341	10,056,200
Total Current Assets	404,819,241	369,112,564
Property, plant and equipment, net	126,417,723	105,364,251
Land use rights, net	24,227,992	23,576,300
Equity method investment	8,579,872	8,718,133
Loan receivable	45,240,000	39,834,173
Other non-current assets	2,445,957	4,861,075
Total Assets	611,730,785	551,466,496
Current Liabilities
Accounts payable	6,525,540	9,681,835
Other payables and accrued expenses	49,276,574	57,462,563
Income tax payable	8,689,920	4,510,986
Total Current Liabilities	64,492,034	71,655,384
Deferred income	4,180,364	4,525,867
Other liabilities	7,538,073	8,323,446
Total Liabilities	76,210,471	84,504,697
Stockholders’ Equity
Common stock: par value $0.0001; 1,000,000,000 shares and 100,000,000 shares authorized at June 30, 2016 and December 31, 2015, respectively; 29,061,130 and 28,835,053 shares issued at June 30, 2016 and December 31, 2015, respectively; 26,806,426 and 26,580,349 shares outstanding at June 30, 2016 and December 31, 2015, respectively	2,906	2,884
Additional paid-in capital	117,265,271	105,079,845
Treasury stock: 2,254,704 shares at June 30, 2016 and December 31, 2015, at cost	(56,425,094)	(56,425,094)
Retained earnings	390,654,384	333,704,094
Accumulated other comprehensive income	(8,889,230)	(18,605)
Total equity attributable to China Biologic Products, Inc.	442,608,237	382,343,124
Noncontrolling interest	92,912,077	84,618,675
Total Stockholders’ Equity	535,520,314	466,961,799
Commitments and contingencies
Total Liabilities and Stockholders’ Equity	$ 611,730,785	$ 551,466,496

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2016	Dec. 31, 2015
Common Stock, Par Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	1,000,000,000	100,000,000
Common Stock, Shares, Issued	29,061,130	28,835,053
Common Stock, Shares, Outstanding	26,806,426	26,580,349
Treasury Stock, Shares	2,254,704	2,254,704

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Sales	$ 91,421,155	$ 79,068,452	$ 177,008,866	$ 149,422,783
Cost of sales	31,482,146	27,054,626	65,525,581	51,516,201
Gross profit	59,939,009	52,013,826	111,483,285	97,906,582
Operating expenses
Selling expenses	3,026,457	2,604,660	4,254,127	4,555,348
General and administrative expenses	12,573,683	8,121,390	23,901,696	15,974,585
Research and development expenses	1,303,815	1,046,985	2,398,538	2,389,307
Income from operations	43,035,054	40,240,791	80,928,924	74,987,342
Other income (expenses)
Equity in income (loss) of an equity method investee	259,850	(666,233)	43,535	(761,300)
Interest expense	(88,528)	(675,860)	(177,078)	(1,432,681)
Interest income	1,292,069	1,467,135	3,043,209	2,843,982
Total other income, net	1,463,391	125,042	2,909,666	650,001
Earnings before income tax expense	44,498,445	40,365,833	83,838,590	75,637,343
Income tax expense	7,006,764	6,123,661	13,613,867	11,739,811
Net income	37,491,681	34,242,172	70,224,723	63,897,532
Less: Net income attributable to noncontrolling interest	6,738,646	7,518,213	13,274,433	14,011,101
Net income attributable to China Biologic Products, Inc.	$ 30,753,035	$ 26,723,959	$ 56,950,290	$ 49,886,431
Net income per share of common stock:
Basic	$ 1.12	$ 1.05	$ 2.08	$ 1.96
Diluted	$ 1.1	$ 0.99	$ 2.05	$ 1.86
Weighted average shares used in computation:
Basic	26,698,996	25,019,039	26,642,461	24,918,517
Diluted	27,152,560	26,320,773	27,145,470	26,265,857
Net income	$ 37,491,681	$ 34,242,172	$ 70,224,723	$ 63,897,532
Other comprehensive income:
Foreign currency translation adjustment, net of nil income taxes	(13,267,360)	1,463,605	(10,697,608)	609,243
Comprehensive income	24,224,321	35,705,777	59,527,115	64,506,775
Less: Comprehensive income attributable to noncontrolling interest	4,468,767	7,831,571	11,447,450	14,286,683
Comprehensive income attributable to China Biologic Products, Inc.	$ 19,755,554	$ 27,874,206	$ 48,079,665	$ 50,220,092

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 70,224,723	$ 63,897,532
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	4,590,028	4,123,599
Amortization	438,916	415,231
Loss on sale of property, plant and equipment and land use rights	115,075	313,529
Allowance for doubtful accounts - accounts receivable, net	6,604	35,372
Allowance for doubtful accounts - other receivables and prepayments	0	796
Allowance for doubtful accounts - other non-current assets	1,225,200	0
Write-down of obsolete inventories	61,497	16,750
Deferred tax (benefit) expense	(1,584,958)	167,921
Share-based compensation	9,307,099	4,033,482
Equity in (income) loss of an equity method investee	(43,535)	761,300
Excess tax benefits from share-based compensation arrangements	0	(288,681)
Change in operating assets and liabilities:
Accounts receivable	(13,856,209)	(18,835,493)
Prepayment and other current assets	2,433,998	(1,165,997)
Inventories	(12,522,807)	(25,272,719)
Accounts payable	(3,001,361)	10,123,561
Other payables and accrued expenses	(4,465,594)	(2,391,597)
Deferred income	(255,394)	(149,708)
Income tax payable	4,339,536	(1,223,601)
Net cash provided by operating activities	57,012,818	34,561,277
CASH FLOWS FROM INVESTING ACTIVITIES:
Payment for property, plant and equipment	(25,222,545)	(16,486,212)
Payment for intangible assets and land use rights	(1,351,789)	(4,205,678)
Refund of deposits related to land use right	6,461,924	0
Proceeds from sale of property, plant and equipment and land use rights	100,424	559,029
Long-term loan lent to a third party	(6,331,518)	0
Net cash used in investing activities	(26,343,504)	(20,132,861)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from stock option exercised	2,364,952	771,164
Repayment of short-term bank loans	0	(97,910,360)
Maturity of deposit as security for bank loans	37,756,405	31,985,122
Excess tax benefits from share-based compensation arrangements	0	288,681
Dividend paid by subsidiaries to noncontrolling interest shareholders	(7,921,952)	0
Net proceeds from reissuance of treasury stock	0	80,583,959
Dividend to the trial court to be held in escrow as to dispute with Jie’an	0	(3,690,814)
Net cash provided by financing activities	32,199,405	12,027,752
EFFECT OF FOREIGN EXCHANGE RATE CHANGES ON CASH	(3,772,623)	(661,684)
NET INCREASE IN CASH AND CASH EQUIVALENTS	59,096,096	25,794,484
Cash and cash equivalents at beginning of period	144,937,893	80,820,224
Cash and cash equivalents at end of period	204,033,989	106,614,708
Supplemental cash flow information
Cash paid for income taxes	10,841,209	12,829,660
Cash paid for interest expense	0	1,428,614
Noncash investing and financing activities:
Acquisition of property, plant and equipment included in payables	$ 9,312,476	$ 231,397

BASIS OF PRESENTATION, SIGNIFIC

BASIS OF PRESENTATION, SIGNIFICANT CONCENTRATION AND RISKS	6 Months Ended
	Jun. 30, 2016
Basis Of Presentation Significant Concentration and Risks [Abstract]
BASIS OF PRESENTATION, SIGNIFICANT CONCENTRATION AND RISKS	NOTE 1 – BASIS OF PRESENTATION, SIGNIFICANT CONCENTRATION AND RISKS (a) Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as permitted by rules and regulations of the U.S. Securities and Exchange Commission (“SEC”). The December 31, 2015 consolidated balance sheet was derived from the audited consolidated financial statements of China Biologic Products, Inc. (the “Company”). The accompanying unaudited consolidated financial statements should be read in conjunction with the December 31, 2015 audited consolidated financial statements of the Company included in the Company’s annual report on Form 10-K for the year ended December 31, 2015. In the opinion of management, all adjustments (which include normal recurring adjustments) necessary to present a fair statement of the financial position as of June 30, 2016, the results of operations for the three and six months ended June 30, 2016 and 2015, and cash flows for the six months ended June 30, 2016 and 2015, have been made. All significant intercompany transactions and balances are eliminated on consolidation. The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the useful lives of property, plant and equipment and intangibles with definite lives, the allowances for doubtful accounts, the fair value determinations of stock compensation awards, the realizability of deferred tax assets and inventories, the recoverability of intangible assets, land use rights, property, plant and equipment, equity method investment and loan receivable, and accruals for income tax uncertainties and other contingencies. (b) Significant Concentration and Risks The Company’s operations are carried out in the People’s Republic of China (the “PRC”) and are subject to specific considerations and significant risks not typically associated with companies in North America and Western Europe. Accordingly, the Company’s business, financial condition and results of operations may be influenced by the political, economic and legal environment in the PRC, and by the general state of the PRC economy. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other matters. The Company maintains cash and deposit balances at financial institutions which, from time to time, may exceed Federal Deposit Insurance Corporation insured limits for its bank accounts located in the United States or may exceed Hong Kong Deposit Protection Board insured limits for its bank accounts located in Hong Kong or may exceed the insured limits for its bank accounts in China established by China Deposit Insurance Fund Management Institution. Total cash at banks and deposits as of June 30, 2016 and December 31, 2015 amounted to $ 203,421,844 182,291,723 2,946,043 3,020,569 The Company’s two major products are human albumin and human immunoglobulin for intravenous injection (“IVIG”). Human albumin accounted for 41.2 35.7 39.7 36.9 33.6 43.1 36.6 44.8 Substantially all of the Company’s customers are located in the PRC. There were no customers that individually comprised 10% or more of the total sales during the three months and six months ended June 30, 2016 and June 30, 2015. There was no customer represented more than 10% of accounts receivables as at June 30, 2016 and December 31, 2015, respectively. The Company performs ongoing credit evaluations of its customers’ financial condition and, generally, requires no collateral from its customers. There was one supplier, namely, Xinjiang Deyuan Bioengineering Co., Ltd. (“Xinjiang Deyuan”), that comprised 10% or more of the total purchases for the three months and six months ended June 30, 2016. No supplier that comprised 10% or more of the total purchases for the three months and six months ended June 30, 2015. There was one supplier that represented more than 10% of accounts payables as at June 30, 2016 and December 31, 2015, respectively.

ACCOUNTS RECEIVABLE

ACCOUNTS RECEIVABLE	6 Months Ended
	Jun. 30, 2016
Accounts Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
ACCOUNTS RECEIVABLE	NOTE 2 – ACCOUNTS RECEIVABLE June 30, 2016 December 31, 2015 USD USD Accounts receivable 38,699,584 25,588,593 Less: Allowance for doubtful accounts (440,908) (443,624) Total 38,258,676 25,144,969 For the Six Months Ended June 30, June 30, 2016 2015 USD USD Beginning balance 443,624 433,948 Provisions 6,604 35,372 Recoveries - - Write-offs - - Foreign currency translation adjustment (9,320) 1,872 Ending balance 440,908 471,192

INVENTORIES

INVENTORIES	6 Months Ended
	Jun. 30, 2016
Inventory Disclosure [Abstract]
INVENTORIES	NOTE 3 – INVENTORIES June 30, 2016 December 31, 2015 USD USD Raw materials 68,089,945 57,418,230 Work-in-process 32,894,873 27,401,062 Finished goods 35,053,399 41,576,020 Total 136,038,217 126,395,312 An inventory write-down of $ 1,937 12,174 61,497 16,750

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	6 Months Ended
	Jun. 30, 2016
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	NOTE 4 – PROPERTY, PLANT AND EQUIPMENT June 30, 2016 December 31, 2015 USD USD Buildings 35,384,230 31,505,133 Machinery and equipment 54,090,284 54,640,502 Furniture, fixtures, office equipment and vehicles 7,961,117 7,859,951 Total property, plant and equipment, gross 97,435,631 94,005,586 Accumulated depreciation (34,659,056) (31,521,859) Total property, plant and equipment, net 62,776,575 62,483,727 Construction in progress 50,951,052 26,115,927 Prepayment for property, plant and equipment 12,690,096 16,764,597 Property, plant and equipment, net 126,417,723 105,364,251 Depreciation expense for the three months ended June 30, 2016 and 2015 was $ 2,322,405 1,922,579 4,590,028 4,123,599

DEPOSITS RELATED TO LAND USE RI

DEPOSITS RELATED TO LAND USE RIGHTS	6 Months Ended
	Jun. 30, 2016
Deposits Related To Land Use Rights [Abstract]
DEPOSITS RELATED TO LAND USE RIGHTS	NOTE 5 – DEPOSITS RELATED TO LAND USE RIGHTS In 2012, Guizhou Taibang made a refundable payment of RMB 83,400,000 12,576,720 13,000,000 1,960,400 10,000,000 1,508,000 16,082,462 2,425,235 18,015,279 2,716,704

LOAN RECEIVABLE

LOAN RECEIVABLE	6 Months Ended
	Jun. 30, 2016
Loans Receivable [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
LOAN RECEIVABLE	NOTE 6 – LOAN RECEIVABLE In August 2015, the Company entered into a cooperation agreement with Xinjiang Deyuan and the controlling shareholder of Xinjiang Deyuan. Pursuant to the agreement, Guizhou Taibang agreed to provide Xinjiang Deyuan with interest-bearing loans at an interest rate of 6 300,000,000 45,240,000 July 31, 2018 Deyuan Shareholder’s 58.02% equity interest in Xinjiang Deyuan 258,663,461 39,006,450 41,336,539 6,331,518 Interest income of $ 694,839 1,347,145

INCOME TAX

INCOME TAX	6 Months Ended
	Jun. 30, 2016
Income Tax Disclosure [Abstract]
INCOME TAX	NOTE 7 – INCOME TAX In October 2014, Shandong provincial government granted Shandong Taibang the High and New Technology Enterprise certificate. This certificate entitled Shandong Taibang to enjoy a preferential income tax rate of 15 According to Cai Shui [2011] No. 58 dated July 27, 2011, Guizhou Taibang, being a qualified enterprise located in the western region of PRC, enjoys a preferential income tax rate of 15 The Company’s effective income tax rates were 16 15 16 16 As of and for the three months ended June 30, 2016, the Company did not have any unrecognized tax benefits and thus no interest and penalties related to unrecognized tax benefits were recorded. In addition, the Company does not expect that the amount of unrecognized tax benefits to change significantly within the next 12 months.

OPTIONS AND NONVESTED SHARES

OPTIONS AND NONVESTED SHARES	6 Months Ended
	Jun. 30, 2016
Equity [Abstract]
OPTIONS AND NONVESTED SHARES	NOTE 8 – OPTIONS AND NONVESTED SHARES Options Weighted Average Weighted Remaining Aggregate Average Exercise Contractual Term Intrinsic Number of Options Price in Years Value USD USD Outstanding at December 31, 2015 651,897 10.44 5.24 86,064,461 Granted - Exercised (215,452) 10.98 (22,481,288) Forfeited and expired - Outstanding at June 30, 2016 436,445 10.17 4.75 41,962,999 Vested and expected to vest 436,445 10.17 4.75 41,962,999 Exercisable at June 30, 2016 315,195 10.30 4.20 30,266,012 For the three months ended June 30, 2016 and 2015, the Company recorded stock compensation expense of $ 243,578 337,789 487,156 630,838 At June 30, 2016, approximately $ 162,048 0.17 Nonvested shares Number of Grant date weighted nonvested shares average fair value USD Outstanding at December 31, 2015 669,100 77.49 Granted 31,800 114.42 Vested (10,625) 41.81 Forfeited - - Outstanding at June 30, 2016 690,275 79.74 For the three months ended June 30, 2016 and 2015, the Company recorded stock compensation expense of $ 4,494,126 1,725,724 8,819,943 3,402,644 At June 30, 2016, approximately $ 39,859,443 2.32

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	6 Months Ended
	Jun. 30, 2016
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 9 – FAIR VALUE MEASUREMENTS Management used the following methods and assumptions to estimate the fair value of financial instruments at the relevant balance sheet dates: • Short-term financial instruments (including cash and cash equivalents, time deposits, accounts receivable, other receivables, accounts payable, and other payables and accrued expenses) – The carrying amounts of the short-term financial instruments approximate their fair values because of the short maturity of these instruments. • Loan receivable – The carrying amounts of loan receivable approximate their fair value. The fair value is estimated using discounted cash flow analysis based on the Company’s incremental borrowing rates for similar borrowing.

SALES

SALES	6 Months Ended
	Jun. 30, 2016
Sales [Abstract]
SALES	NOTE 10 – SALES The Company’s sales are primarily derived from the manufacture and sale of Human Albumin and Immunoglobulin products. For the Three Months Ended June 30, June 30, 2016 2015 USD USD Human Albumin 37,707,805 28,202,452 Immunoglobulin products: Human Immunoglobulin for Intravenous Injection 30,673,660 34,075,251 Other Immunoglobulin products 8,205,752 6,650,652 Placenta Polypeptide 10,890,493 7,735,830 Others 3,943,445 2,404,267 Total 91,421,155 79,068,452 For the Six Months Ended June 30, June 30, 2016 2015 USD USD Human Albumin 70,336,659 55,095,482 Immunoglobulin products: Human Immunoglobulin for Intravenous Injection 64,831,422 66,941,041 Other Immunoglobulin products 17,106,067 10,984,774 Placenta Polypeptide 16,598,897 12,288,034 Others 8,135,821 4,113,452 Total 177,008,866 149,422,783

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 11 – COMMITMENTS AND CONTINGENCIES Commitments As of June 30, 2016, commitments outstanding for the purchase of property, plant and equipment approximated $ 25.4 As of June 30, 2016, commitments outstanding for the purchase of plasma from 2016 to 2018 64.5 Legal proceedings Dispute with Jie’an over Certain Capital Injection into Guizhou Taibang In May 2007, a 91 20,000,000 9 50,960,000 7,684,768 21.4 1,800,000 20,000,000 50,960,000 7,684,768 6,480,000 977,184 In June 2007, Jie’an brought a lawsuit against Guizhou Taibang, alleging that it had a right to acquire the 18,200,000 During the second quarter of 2010, Jie’an requested that Guizhou Taibang register its 1.8 In December 2013, Jie’an brought a third lawsuit against Guizhou Taibang, requesting Guizhou Taibang to register 1.8 13,809,197 2,082,427 1.8 18,339,227 2,765,555 22,639,227 3,413,995 In November 2013, Guizhou Taibang held a shareholders meeting and the shareholders passed resolutions, or the November 2013 Resolutions, that, inter alia, (i) determined that it was no longer necessary for Guizhou Taibang to obtain additional capital from investors; (ii) rejected Jie’an’s request that Jie’an subscribe for additional shares of Guizhou Taibang alone and one or more other shareholders reduce their shareholding in Guizhou Taibang; and (iii) approved the issuance of a total of 20,000,000 In March 2014, Guizhou Taibang held another shareholders meeting and the shareholders passed resolutions, or the March 2014 Resolutions, that, inter alia, re-calculated the ownership percentage in Guizhou Taibang based on the November 2013 Resolutions and the additional capital injections from existing shareholders. Guizhou Taibang subsequently updated the registration with the local AIC regarding the additional capital injections in August 2014. In September 2014, Jie’an and another minority shareholder of Guizhou Taibang filed a lawsuit against Guizhou Taibang, requesting that the court declare both the November 2013 Resolutions and the March 2014 Resolutions void and instruct Guizhou Taibang to withdraw the AIC registration. In November 2014, the trial court suspended this case pending the final outcome of the third lawsuit filed by Jie’an. In October 2015, the trial court denied their request. In May 2016, the appellate court vacated the trial court’s decision to uphold Guizhou Taibang’s shareholders resolution, and remanded the case for retrial. If the pending cases with Jie’an are ultimately ruled in Jie’an’s favor, the ownership interest in Guizhou Taibang may be diluted to 84 18,339,227 2,765,555 1.8 5,040,000 760,032 1,440,000 217,152 3,836,151 578,492 Dispute with Certain Individual Investor over Certain Capital Injection into Guizhou Taibang In part due to the invalidity of the Equity Purchase Agreement with certain alleged strategic investors in May 2007, which was never approved or ratified by Guizhou Taibang’s shareholders, such investors’ equity ownership in Guizhou Taibang and the related increase in registered capital of Guizhou Taibang have never been registered with the local AIC. In January 2010, one individual among such investors brought a lawsuit against Guizhou Taibang requesting to register his 14.35 In October 2010, the trial court denied such individual investor’s right as shareholder of Guizhou Taibang and his entitlement to share the dividends, which ruling was reaffirmed after a re-trial by the same trial court in December 2012. After such ruling, Guizhou Taibang attempted to return the originally received fund of RMB 34,160,000 5,151,328 11,200,000 1,688,960 As of June 30, 2016, Guizhou Taibang had maintained, on its balance sheet, payables to the investors of RMB 34,160,000 5,151,328 18,486,868 2,787,820 341,600 51,513 1

NET INCOME PER SHARE

NET INCOME PER SHARE	6 Months Ended
	Jun. 30, 2016
Earnings Per Share [Abstract]
NET INCOME PER SHARE	NOTE 12 - NET INCOME PER SHARE For the Three Months Ended June 30, 2016 June 30, 2015 USD USD Net income attributable to China Biologic Products, Inc. 30,753,035 26,723,959 Earnings allocated to participating nonvested shares (775,050) (573,820) Net income used in basic/diluted net income per common stock 29,977,985 26,150,139 Weighted average shares used in computing basic net income per common stock 26,698,996 25,019,039 Diluted effect of stock options 453,564 1,301,734 Weighted average shares used in computing diluted net income per common stock 27,152,560 26,320,773 Net income per common stock – basic 1.12 1.05 Net income per common stock – diluted 1.10 0.99 During the three months ended June 30, 2016 and 2015, no option was antidilutive or excluded from the calculation of diluted net income per common stock. For the Six Months Ended June 30, 2016 June 30, 2015 USD USD Net income attributable to China Biologic Products, Inc. 56,950,290 49,886,431 Earnings allocated to participating nonvested shares (1,422,528) (1,076,448) Net income used in basic/diluted net income per common stock 55,527,762 48,809,983 Weighted average shares used in computing basic net income per common stock 26,642,461 24,918,517 Diluted effect of stock options 503,009 1,347,340 Weighted average shares used in computing diluted net income per common stock 27,145,470 26,265,857 Net income per common stock – basic 2.08 1.96 Net income per common stock – diluted 2.05 1.86 During the six months ended June 30, 2016 and 2015, no option was antidilutive or excluded from the calculation of diluted net income per common stock.

RECENTLY ISSUED ACCOUNTING PRON

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS	6 Months Ended
	Jun. 30, 2016
Accounting Changes and Error Corrections [Abstract]
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS	Note 13 – RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), which modified lease accounting for both lessees and lessors to increase transparency and comparability by recognizing lease assets and lease liabilities by lessees for those leases classified as operating leases under previous accounting standards and disclosing key information about leasing arrangements. ASU 2016-02 is effective for public companies for annual reporting periods, and interim periods within those years, beginning after December 15, 2018. Early adoption is permitted. In March 2016, the FASB issued ASU No. 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (“ASU 2016-09”), which simplified certain aspects of the accounting for share-based payment transactions, including income taxes, classification of awards and classification in the statement of cash flows. This standard will be effective for public companies for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years.

SUBSEQUENT EVENT

SUBSEQUENT EVENT	6 Months Ended
	Jun. 30, 2016
Subsequent Events [Abstract]
SUBSEQUENT EVENT	NOTE 14 – SUBSEQUENT EVENT In June 2016, the Company entered into a RMB 40,000,000 6,032,000 6 The loan is unsecured and due on the earlier of 1) within five days after Xinjiang Deyuan obtaining other loans from financial institutions, or 2) September 20, 2016. 40,000,000 6,032,000 On July 31, 2016, Guiyang Dalin Biologic Technologies Co., Ltd. (“Guiyang Dalin”), Guizhou Taibang and Jie’an and Shenzhen Yigong Shengda Technology Co., Ltd. (“Yigong Shengda”), two noncontrolling interest holders of Guizhou Taibang, entered into an agreement, pursuant to which Jie’an and Yigong Shengda agreed to withdraw all of their capital contribution in Guizhou Taibang for an aggregate consideration of RMB 415.0 62.6 90.0 13.6

ACCOUNTS RECEIVABLE (Tables)

ACCOUNTS RECEIVABLE (Tables)	6 Months Ended
	Jun. 30, 2016
Receivables [Abstract]
SCHEDULE OF ACCOUNTS RECEIVABLE	Accounts receivable at June 30, 2016 and December 31, 2015 consisted of the following: June 30, 2016 December 31, 2015 USD USD Accounts receivable 38,699,584 25,588,593 Less: Allowance for doubtful accounts (440,908) (443,624) Total 38,258,676 25,144,969
SCHEDULE OF ACTIVITIES IN ALLOWANCE FOR DOUBTFUL ACCOUNTS	The activity in the allowance for doubtful accounts-accounts receivable for the six months ended June 30, 2016 and 2015 are as follows: For the Six Months Ended June 30, June 30, 2016 2015 USD USD Beginning balance 443,624 433,948 Provisions 6,604 35,372 Recoveries - - Write-offs - - Foreign currency translation adjustment (9,320) 1,872 Ending balance 440,908 471,192

INVENTORIES (Tables)

INVENTORIES (Tables)	6 Months Ended
	Jun. 30, 2016
Inventory Disclosure [Abstract]
SCHEDULE OF INVENTORIES	Inventories at June 30, 2016 and December 31, 2015 consisted of the following: June 30, 2016 December 31, 2015 USD USD Raw materials 68,089,945 57,418,230 Work-in-process 32,894,873 27,401,062 Finished goods 35,053,399 41,576,020 Total 136,038,217 126,395,312

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	6 Months Ended
	Jun. 30, 2016
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY, PLANT AND EQUIPMENT	Property, plant and equipment at June 30, 2016 and December 31, 2015 consisted of the following: June 30, 2016 December 31, 2015 USD USD Buildings 35,384,230 31,505,133 Machinery and equipment 54,090,284 54,640,502 Furniture, fixtures, office equipment and vehicles 7,961,117 7,859,951 Total property, plant and equipment, gross 97,435,631 94,005,586 Accumulated depreciation (34,659,056) (31,521,859) Total property, plant and equipment, net 62,776,575 62,483,727 Construction in progress 50,951,052 26,115,927 Prepayment for property, plant and equipment 12,690,096 16,764,597 Property, plant and equipment, net 126,417,723 105,364,251

OPTIONS AND NONVESTED SHARES (T

OPTIONS AND NONVESTED SHARES (Tables)	6 Months Ended
	Jun. 30, 2016
Options and Nonvested Shares [Abstract]
SCHEDULE OF STOCK OPTIONS ACTIVITY	A summary of stock options activity for the six months ended June 30, 2016 is as follow: Weighted Average Weighted Remaining Aggregate Average Exercise Contractual Term Intrinsic Number of Options Price in Years Value USD USD Outstanding at December 31, 2015 651,897 10.44 5.24 86,064,461 Granted - Exercised (215,452) 10.98 (22,481,288) Forfeited and expired - Outstanding at June 30, 2016 436,445 10.17 4.75 41,962,999 Vested and expected to vest 436,445 10.17 4.75 41,962,999 Exercisable at June 30, 2016 315,195 10.30 4.20 30,266,012
SCHEDULE OF NONVESTED SHARES ACTIVITY	A summary of nonvested shares activity for the six months ended June 30, 2016 is as follows: Number of Grant date weighted nonvested shares average fair value USD Outstanding at December 31, 2015 669,100 77.49 Granted 31,800 114.42 Vested (10,625) 41.81 Forfeited - - Outstanding at June 30, 2016 690,275 79.74

SALES (Tables)

SALES (Tables)	6 Months Ended
	Jun. 30, 2016
Sales Disclosure [Abstract]
SCHEDULE OF SALES BY PRODUCT TYPE	For the Three Months Ended June 30, June 30, 2016 2015 USD USD Human Albumin 37,707,805 28,202,452 Immunoglobulin products: Human Immunoglobulin for Intravenous Injection 30,673,660 34,075,251 Other Immunoglobulin products 8,205,752 6,650,652 Placenta Polypeptide 10,890,493 7,735,830 Others 3,943,445 2,404,267 Total 91,421,155 79,068,452 For the Six Months Ended June 30, June 30, 2016 2015 USD USD Human Albumin 70,336,659 55,095,482 Immunoglobulin products: Human Immunoglobulin for Intravenous Injection 64,831,422 66,941,041 Other Immunoglobulin products 17,106,067 10,984,774 Placenta Polypeptide 16,598,897 12,288,034 Others 8,135,821 4,113,452 Total 177,008,866 149,422,783

NET INCOME PER SHARE (Tables)

NET INCOME PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2016
Net Income Loss Per Share Disclosure [Abstract]
SCHEDULE OF EPS - BASIC AND DILUTED	For the Three Months Ended June 30, 2016 June 30, 2015 USD USD Net income attributable to China Biologic Products, Inc. 30,753,035 26,723,959 Earnings allocated to participating nonvested shares (775,050) (573,820) Net income used in basic/diluted net income per common stock 29,977,985 26,150,139 Weighted average shares used in computing basic net income per common stock 26,698,996 25,019,039 Diluted effect of stock options 453,564 1,301,734 Weighted average shares used in computing diluted net income per common stock 27,152,560 26,320,773 Net income per common stock – basic 1.12 1.05 Net income per common stock – diluted 1.10 0.99 The following table sets forth the computation of basic and diluted net income per share for the periods indicated: For the Six Months Ended June 30, 2016 June 30, 2015 USD USD Net income attributable to China Biologic Products, Inc. 56,950,290 49,886,431 Earnings allocated to participating nonvested shares (1,422,528) (1,076,448) Net income used in basic/diluted net income per common stock 55,527,762 48,809,983 Weighted average shares used in computing basic net income per common stock 26,642,461 24,918,517 Diluted effect of stock options 503,009 1,347,340 Weighted average shares used in computing diluted net income per common stock 27,145,470 26,265,857 Net income per common stock – basic 2.08 1.96 Net income per common stock – diluted 2.05 1.86

BASIS OF PRESENTATION, SIGNIF26

BASIS OF PRESENTATION, SIGNIFICANT CONCENTRATION AND RISKS (Narrative) (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2016USD ($)	Jun. 30, 2015	Jun. 30, 2016USD ($)	Jun. 30, 2015	Dec. 31, 2015USD ($)
Basis Of Presentation Significant Concentration And Risk [Line Items]
Total cash at banks and deposits including insured amount	$ 203,421,844		$ 203,421,844		$ 182,291,723
Cash, Insured Amount	$ 2,946,043		$ 2,946,043		$ 3,020,569
Customers that individually comprised 10% or more of the total sales			0	0
Suppliers that comprised 10% or more of the total purchases	1	0	1	0
Customers represented 10% or more of trade receivables	0		0		0
Suppliers that represented more than 10% of accounts payables	1		1		1
Human Albumin [Member]
Basis Of Presentation Significant Concentration And Risk [Line Items]
Major product sales percentage	41.20%	35.70%	39.70%	36.90%
Human Immunoglobulin For Intravenous Injection [Member]
Basis Of Presentation Significant Concentration And Risk [Line Items]
Major product sales percentage	33.60%	43.10%	36.60%	44.80%

ACCOUNTS RECEIVABLE (Schedule O

ACCOUNTS RECEIVABLE (Schedule Of Accounts Receivable) (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	$ 38,699,584	$ 25,588,593
Less: Allowance for doubtful accounts	(440,908)	(443,624)
Total	$ 38,258,676	$ 25,144,969

ACCOUNTS RECEIVABLE (Schedule28

ACCOUNTS RECEIVABLE (Schedule Of Activity in the Allowance for Doubtful Accounts) (Details) - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Valuation and Qualifying Accounts Disclosure [Line Items]
Beginning balance	$ 443,624	$ 433,948
Provisions	6,604	35,372
Recoveries	0	0
Write-offs	0	0
Foreign currency translation adjustment	(9,320)	1,872
Ending balance	$ 440,908	$ 471,192

INVENTORIES (Narrative) (Detail

INVENTORIES (Narrative) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Write-down of obsolete inventories	$ 1,937	$ 12,174	$ 61,497	$ 16,750

INVENTORIES (Schedule Of Invent

INVENTORIES (Schedule Of Inventories) (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Inventory [Line Items]
Raw materials	$ 68,089,945	$ 57,418,230
Work-in-process	32,894,873	27,401,062
Finished goods	35,053,399	41,576,020
Total	$ 136,038,217	$ 126,395,312

PROPERTY, PLANT AND EQUIPMENT31

PROPERTY, PLANT AND EQUIPMENT (Narrative) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Depreciation	$ 2,322,405	$ 1,922,579	$ 4,590,028	$ 4,123,599

PROPERTY, PLANT AND EQUIPMENT32

PROPERTY, PLANT AND EQUIPMENT (Schedule Of Property Plant And Equipment) (Details) - USD ($)	Jun. 30, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	$ 97,435,631	$ 94,005,586
Accumulated depreciation	(34,659,056)	(31,521,859)
Total property, plant and equipment, net	62,776,575	62,483,727
Construction in progress	50,951,052	26,115,927
Prepayment for property, plant and equipment	12,690,096	16,764,597
Property, plant and equipment, net	126,417,723	105,364,251
Buildings [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	35,384,230	31,505,133
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	54,090,284	54,640,502
Furniture, Fixtures, Office Equipment and Vehicles [Member]
Property, Plant and Equipment [Line Items]
Total property, plant and equipment, gross	$ 7,961,117	$ 7,859,951

DEPOSITS RELATED TO LAND USE 33

DEPOSITS RELATED TO LAND USE RIGHTS (Narrative) (Details)	12 Months Ended
	Dec. 31, 2012USD ($)	Dec. 31, 2012CNY (¥)	Jun. 30, 2016USD ($)	Jun. 30, 2016CNY (¥)	Apr. 30, 2016USD ($)	Apr. 30, 2016CNY (¥)	Jan. 31, 2014USD ($)	Jan. 31, 2014CNY (¥)	Dec. 31, 2013USD ($)	Dec. 31, 2013CNY (¥)
Refunded deposits related to land use rights			$ 2,716,704	¥ 18,015,279	$ 2,425,235	¥ 16,082,462	$ 1,508,000	¥ 10,000,000	$ 1,960,400	¥ 13,000,000
Use Rights [Member] | Land [Member]
Payment For Refundable Deposits	$ 12,576,720	¥ 83,400,000

LOAN RECEIVABLE (Narrative) (De

LOAN RECEIVABLE (Narrative) (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Mar. 31, 2016USD ($)	Mar. 31, 2016CNY (¥)	Dec. 31, 2015USD ($)	Dec. 31, 2015CNY (¥)	Aug. 31, 2015USD ($)	Aug. 31, 2015CNY (¥)
Accounts, Notes, Loans and Financing Receivable [Line Items]
Loan receivable	$ 45,240,000		$ 45,240,000				$ 39,834,173
Interest income	$ 1,292,069	$ 1,467,135	$ 3,043,209	$ 2,843,982
Debt interest percentage [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Debt Instrument, Collateral			Deyuan Shareholders 58.02% equity interest in Xinjiang Deyuan
Xinjiang Deyuan [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Loan receivable							$ 39,006,450	¥ 258,663,461
Cooperation Agreement Loan Principal Amount									$ 45,240,000	¥ 300,000,000
Debt Instrument, Interest Rate, Stated Percentage	6.00%		6.00%						6.00%	6.00%
Debt Instrument, Maturity Date			Jul. 31, 2018
Loan receivable					$ 6,331,518	¥ 41,336,539
Interest income	$ 694,839		$ 1,347,145

INCOME TAX (Narrative) (Details

INCOME TAX (Narrative) (Details)	3 Months Ended		6 Months Ended		36 Months Ended	120 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Dec. 31, 2016	Dec. 31, 2020
Effective income tax rate	16.00%	15.00%	16.00%	16.00%
Shandong Taibang [Member] | Scenario, Forecast [Member]
Preferential Income Tax Rate					15.00%
Guizhou Taibang [Member] | Scenario, Forecast [Member]
Preferential Income Tax Rate						15.00%

OPTIONS AND NONVESTED SHARES (N

OPTIONS AND NONVESTED SHARES (Narrative) (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Warrants and Options Disclosure [Line Items]
Stock compensation expense with respect to non-vested stock option	$ 162,048		$ 162,048
Stock compensation expense to be recognized with respect to non-vested stock option			2 months 1 day
Stock compensation expense to be recognized with respect to non-vested shares	39,859,443		$ 39,859,443
Stock compensation expense with respect to non-vested shares weighted average vesting period			2 years 3 months 25 days
General and Administrative Expense [Member]
Warrants and Options Disclosure [Line Items]
Stock compensation expense related to options	243,578	$ 337,789	$ 487,156	$ 630,838
Stock compensation expense related to nonvested shares	$ 4,494,126	$ 1,725,724	$ 8,819,943	$ 3,402,644

SCHEDULE OF STOCK OPTIONS ACTIV

SCHEDULE OF STOCK OPTIONS ACTIVITY (Details) - Stock Option [Member] - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Outstanding at beginning	651,897
Number of Options, Granted	0
Number of Options, Exercised	(215,452)
Number of Options, Forfeited and expired	0
Number of Options, Outstanding at ending	436,445	651,897
Number of Options, Vested and expected to vest	436,445
Number of Options, Exercisable	315,195
Weighted Average Exercise Price, Outstanding at beginning	$ 10.44
Weighted Average Exercise Price, Exercised	10.98
Weighted Average Exercise Price, Outstanding at ending	10.17	$ 10.44
Weighted Average Exercise Price, Vested and expected to vest	10.17
Weighted Average Exercise Price, Exercisable	$ 10.3
Weighted Average Remaining Contractual Term in Years, Outstanding	4 years 9 months	5 years 2 months 26 days
Weighted Average Remaining Contractual Term in Years, Vested and expected to vest	4 years 9 months
Weighted Average Remaining Contractual Term in Years, Exercisable	4 years 2 months 12 days
Aggregate Intrinsic Value, Outstanding at beginning	$ 86,064,461
Aggregate Intrinsic Value, Exercised	(22,481,288)
Aggregate Intrinsic Value, Outstanding at ending	41,962,999	$ 86,064,461
Aggregate Intrinsic Value Vested and expected to vest	41,962,999
Aggregate Intrinsic Value, Exercisable	$ 30,266,012

SCHEDULE OF NONVESTED SHARES AC

SCHEDULE OF NONVESTED SHARES ACTIVITY (Details) - Non Vested Shares [Member]	6 Months Ended
	Jun. 30, 2016$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of nonvested shares, Outstanding at beginning | shares	669,100
Number of nonvested shares, Granted | shares	31,800
Number of nonvested shares, Vested | shares	(10,625)
Number of nonvested shares, Forfeited | shares	0
Number of nonvested shares, Outstanding at ending | shares	690,275
Grant date weighted average fair value, Outstanding at beginning | $ / shares	$ 77.49
Grant date weighted average fair value, Granted | $ / shares	114.42
Grant date weighted average fair value, Vested | $ / shares	41.81
Grant date weighted average fair value, Forfeited | $ / shares	0
Grant date weighted average fair value, Outstanding at ending | $ / shares	$ 79.74

SCHEDULE OF SALES BY PRODUCT TY

SCHEDULE OF SALES BY PRODUCT TYPE (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Product Information [Line Items]
Sales	$ 91,421,155	$ 79,068,452	$ 177,008,866	$ 149,422,783
Others [Member]
Product Information [Line Items]
Sales	3,943,445	2,404,267	8,135,821	4,113,452
Human Albumin [Member]
Product Information [Line Items]
Sales	37,707,805	28,202,452	70,336,659	55,095,482
Human Immunoglobulin For Intravenous Injection [Member]
Product Information [Line Items]
Sales	30,673,660	34,075,251	64,831,422	66,941,041
Other Immunoglobulin Products [Member]
Product Information [Line Items]
Sales	8,205,752	6,650,652	17,106,067	10,984,774
Placenta Polypeptide [Member]
Product Information [Line Items]
Sales	$ 10,890,493	$ 7,735,830	$ 16,598,897	$ 12,288,034

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Narrative) (Details)	1 Months Ended								3 Months Ended			6 Months Ended				12 Months Ended
	Jul. 31, 2014USD ($)	Jul. 31, 2014CNY (¥)	Nov. 30, 2010USD ($)	Nov. 30, 2010CNY (¥)	Oct. 31, 2010USD ($)	Oct. 31, 2010CNY (¥)	Jun. 30, 2007shares	May 31, 2007USD ($)shares	Jun. 30, 2016USD ($)	Jun. 30, 2015USD ($)	Jun. 30, 2010shares	Jun. 30, 2016USD ($)shares	Jun. 30, 2016CNY (¥)shares	Jun. 30, 2015USD ($)	Jun. 30, 2015CNY (¥)	Dec. 31, 2014USD ($)shares	Dec. 31, 2014CNY (¥)shares	Dec. 31, 2013shares	Jun. 30, 2016CNY (¥)	Nov. 30, 2013shares	Jan. 31, 2010	May 31, 2007CNY (¥)shares
Interest Expense, Total | $									$ 88,528	$ 675,860		$ 177,078		$ 1,432,681
Plasma [Member]
Purchase commitment, period of years												from 2016 to 2018	from 2016 to 2018
Purchase commitment amount | $												$ 64,500,000
Capital Addition Purchase Commitments [Member]
Capital Commitment Amount | $												25,400,000
Dispute with Certain Individual Investor over Certain Capital Injection into Guizhou Taibang [Member]
Controlling interest of Guizhou Taibang's shareholders								91.00%														91.00%
Issuance of an additional 20,000,000 shares of Guizhou Taibang								20,000,000
Remaining 9% noncontrolling interest								9.00%														9.00%
Investors agreed to invest								$ 7,684,768														¥ 50,960,000
21.4%, of Guizhou Taibang's equity interests								21.40%														21.40%
Subscribed for 1,800,000 shares								1,800,000														1,800,000
Share of the 20,000,000 shares being offered								20,000,000														20,000,000
Penalty												$ 51,513	¥ 341,600
Penalty Imposed By The Agreement												1.00%	1.00%
Interest Expense, Total												$ 2,787,820	¥ 18,486,868
Equity Method Investment, Ownership Percentage																					14.35%
Payable to investors									5,151,328			$ 5,151,328							¥ 34,160,000
Guizhou Taibang attempted to return the originally received fund					$ 5,151,328	¥ 34,160,000
Another investor accepted the returned fund			$ 1,688,960	¥ 11,200,000
Dispute with Jie'an over Certain Capital Injection into Guizhou Taibang [Member]
Guizhou Taibang received from investors								$ 7,684,768														¥ 50,960,000
Guizhou Taibang received from Jie'an								$ 977,184														¥ 6,480,000
Jie'an alleged right to acquire common stock shares in a lawsuit							18,200,000
Requested that Guizhou Taibang register its 1.8 million shares of additional capital infusion with the local AIC											1,800,000
Diluted to 84%												84.00%	84.00%
Payables to Jie an for the additional funds received									760,032			$ 760,032							5,040,000
Payables to Jie an for over-paid subscription									217,152			217,152							1,440,000
Payable to Jie an for the accrued interest									$ 578,492			578,492							¥ 3,836,151
Number of shares failed to register																		1,800,000
Common Stock, Capital Shares Reserved for Future Issuance																				20,000,000
Payment to trial court to be held in escrow														$ 3,413,995	¥ 22,639,227
Guizhou Taibang to pay accumulated dividends associated with these shares and the related interest expenses to Jiean	$ 2,082,427	¥ 13,809,197
The appellate court ordered Guizhou Taibang to pay Jiean its share of accumulated dividends associated with these shares plus the related interest expenses																$ 2,765,555	¥ 18,339,227
The appellate court ruled in favor of Jie'an supporting its request to register 1.8 million shares																1,800,000	1,800,000
Jie'an may be entitled to receive accumulated dividends and the related interest expenses												$ 2,765,555	¥ 18,339,227
Jie'an claimed share of Guizhou Taibang's accumulated dividend distributions associated with the 1.8 million shares												1,800,000	1,800,000

NET INCOME PER SHARE - (Schedul

NET INCOME PER SHARE - (Schedule Of Computation Of Basic And Diluted Net Income Per Share (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Net income attributable to China Biologic Products, Inc.	$ 30,753,035	$ 26,723,959	$ 56,950,290	$ 49,886,431
Earnings allocated to participating nonvested shares	(775,050)	(573,820)	(1,422,528)	(1,076,448)
Net income used in basic/diluted net income per common stock	$ 29,977,985	$ 26,150,139	$ 55,527,762	$ 48,809,983
Weighted average shares used in computing basic net income per common stock	26,698,996	25,019,039	26,642,461	24,918,517
Diluted effect of stock options	453,564	1,301,734	503,009	1,347,340
Weighted average shares used in computing diluted net income per common stock	27,152,560	26,320,773	27,145,470	26,265,857
Net income per common stock - basic	$ 1.12	$ 1.05	$ 2.08	$ 1.96
Net income per common stock - diluted	$ 1.1	$ 0.99	$ 2.05	$ 1.86

SUBSEQUENT EVENT (Narrative) (D

SUBSEQUENT EVENT (Narrative) (Details)	1 Months Ended				6 Months Ended
	Aug. 01, 2016USD ($)	Aug. 01, 2016CNY (¥)	Jul. 31, 2016USD ($)	Jul. 31, 2016CNY (¥)	Jun. 30, 2016USD ($)	Jul. 01, 2016USD ($)	Jul. 01, 2016CNY (¥)	Jun. 30, 2016CNY (¥)	Aug. 31, 2015
Xinjiang Deyuan [Member]
Subsequent Event [Line Items]
Notes, Loans and Financing Receivable, Net, Current					$ 6,032,000			¥ 40,000,000
Debt Instrument, Interest Rate, Stated Percentage					6.00%			6.00%	6.00%
Debt Instrument, Maturity Date, Description					The loan is unsecured and due on the earlier of 1) within five days after Xinjiang Deyuan obtaining other loans from financial institutions, or 2) September 20, 2016.
Subsequent Event [Member]
Subsequent Event [Line Items]
Consideration To Noncontrolling Interest Holders For Withdraw All Of Capital Contribution			$ 62,600,000	¥ 415,000,000
Payment Of First Installment To Noncontrolling Interest Holders	$ 13,600,000	¥ 90,000,000
Subsequent Event [Member] | Xinjiang Deyuan [Member]
Subsequent Event [Line Items]
Notes, Loans and Financing Receivable, Net, Current						$ 6,032,000	¥ 40,000,000